Johnson and Johnson gets Chinese nod to import psoriasis drug Tremfya

Johnson and Johnson (JnJ) is positioning Tremfya as a better alternative to Novartis’s Cosentyx as it seeks to take market share away from the treatment, which was launched two years ago and is among the top-selling treatments in the $11 billion global psoriasis market.

New Delhi: China has approved imports of Johnson & Johnson’s Tremfya (guselkumab), the National Medical Products Administration said in a notice on Friday.

The drug will be used to treat moderate to severe plaque psoriasis in adults who are suitable for systemic therapy, the administration said.

J&J is positioning Tremfya as a better alternative to Novartis’s Cosentyx as it seeks to take market share away from the treatment, which was launched two years ago and is among the top-selling treatments in the $11 billion global psoriasis market.

Also Read: JnJ CEO declines to appear at US congressional hearing on carcinogen in baby powder